BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections (the “Acquisition”).
Read the full article: BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50M Financing //
Source: https://www.globenewswire.com/news-release/2024/03/06/2841300/0/en/BiomX-Announces-Entry-into-Merger-Agreement-with-Adaptive-Phage-Therapeutics-and-Concurrent-50-Million-Financing.html